Smith Salley Wealth Management Purchases 2,252 Shares of Johnson & Johnson $JNJ

Smith Salley Wealth Management lifted its position in Johnson & Johnson (NYSE:JNJ) by 4.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 57,834 shares of the company’s stock after purchasing an additional 2,252 shares during the period. Smith Salley Wealth Management’s holdings in Johnson & Johnson were worth $14,137,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Blueline Advisors LLC purchased a new position in shares of Johnson & Johnson in the fourth quarter valued at about $25,000. Cresta Advisors Ltd. bought a new stake in Johnson & Johnson during the 4th quarter valued at approximately $26,000. DecisionPoint Financial LLC raised its stake in Johnson & Johnson by 104.2% during the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock valued at $30,000 after purchasing an additional 75 shares during the period. Family CFO Inc purchased a new position in Johnson & Johnson in the 4th quarter worth approximately $31,000. Finally, Bay Harbor Wealth Management LLC boosted its stake in Johnson & Johnson by 49.0% in the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock worth $31,000 after purchasing an additional 49 shares during the period. Institutional investors own 69.55% of the company’s stock.

Insider Activity

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the sale, the executive vice president directly owned 114,288 shares in the company, valued at approximately $27,560,551.20. This represents a 8.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 1.2%

NYSE JNJ opened at $231.12 on Tuesday. The stock has a 50 day moving average price of $230.41 and a 200-day moving average price of $228.43. Johnson & Johnson has a one year low of $149.74 and a one year high of $251.71. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. The company has a market capitalization of $556.36 billion, a P/E ratio of 26.72, a P/E/G ratio of 2.24 and a beta of 0.26.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.02. The company had revenue of $24.06 billion for the quarter, compared to analysts’ expectations of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. Johnson & Johnson’s quarterly revenue was up 9.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, equities analysts predict that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th were issued a $1.34 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date was Tuesday, May 26th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.3%. Johnson & Johnson’s payout ratio is presently 61.97%.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson announced a more than $1 billion expansion of its Jacksonville, Florida Vision operations, boosting domestic manufacturing, packaging, and distribution capacity for ACUVUE contact lenses. The move is part of a broader $55 billion U.S. investment plan and may support long-term growth and supply-chain resilience. Johnson & Johnson (JNJ) Is Spending More Than $1 Billion On Jacksonville Vision Expansion
• Positive Sentiment: Recent commentary highlights Johnson & Johnson as a quality dividend name with improving pharma momentum, including oncology strength and upside to price targets, which may be helping sentiment around the stock. Pharma Momentum Fuels Johnson & Johnson’s Path to Double-Digit Upside
• Neutral Sentiment: Brokerage coverage remains constructive, with Johnson & Johnson still carrying a “Moderate Buy” consensus rating. This supports the stock, but is not a fresh catalyst on its own. Johnson & Johnson (NYSE:JNJ) Receives Consensus Rating of “Moderate Buy” from Brokerages
• Neutral Sentiment: Additional articles reiterated the Jacksonville expansion story and its strategic role in strengthening JNJ’s Vision business, reinforcing the same positive theme rather than adding a new development. How Johnson & Johnson (JNJ) Is Using U.S. Manufacturing Investment to Strengthen Its Vision Business
• Negative Sentiment: No major negative company-specific headlines were included in the latest batch, so there is little evidence of a fresh catalyst pushing shares lower today.

Analyst Upgrades and Downgrades

JNJ has been the topic of several recent analyst reports. Morgan Stanley set a $283.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, April 15th. Weiss Ratings cut shares of Johnson & Johnson from a “buy (b)” rating to a “buy (b-)” rating in a research note on Monday, June 15th. TD Cowen initiated coverage on shares of Johnson & Johnson in a report on Wednesday, April 8th. They issued a “buy” rating and a $250.00 price target on the stock. Sanford C. Bernstein boosted their price target on shares of Johnson & Johnson from $225.00 to $251.00 and gave the stock a “market perform” rating in a research note on Wednesday, April 15th. Finally, Citigroup increased their price objective on shares of Johnson & Johnson from $274.00 to $285.00 and gave the company a “buy” rating in a report on Tuesday, April 7th. Twenty investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $253.04.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.